01
drip · regulatory intelligence
drip tracks every regulatory body that touches the creator stack. FDA, EU CPNP, PMDA, K-FDA, NMPA, and BIOSECURE. updated monthly by ops + counsel.
02
entries
01
United States · FDA
twelve peptides removed from the 503A Category 2 restricted list. follows the 2026-02-27 HHS announcement signaling cosmetic-peptide market reopening.
relevance to drip. cosmetic-peptide market legitimization clears ahead. the novelty-gateway moat sharpens because shared catalog peptides are now legal again, raising the ceiling on the field. drip-launched novel sequences remain exclusive to their creators regardless.
source · pending citation lock
02
United States · FDA · PCAC
PCAC reviews BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, Epitalon for the 503A bulk substances list.
relevance to drip. none of these are drip discovery candidates. the literature corpus excludes them by construction. the ruling moves market expectations and downstream demand for adjacent novel sequences.
source · pending citation lock
03
United States · FDA · PCAC
PCAC reviews GHK-Cu for the 503A bulk substances list.
relevance to drip. GHK-Cu is the marquee cosmetic peptide. a ruling legitimizing it as a compoundable substance inflates demand for cosmetic peptides generally. direct tailwind for drip creators in the skin / firmness / collagen-synthesis ontology.
source · pending citation lock
03
scope
cosmetic regulatory
peptide-adjacent
cross-cutting
04
cadence
drip ops + counsel review every relevant filing, advisory committee outcome, and rulemaking notice on a monthly cycle. entries land here when they materially change what a creator can ship, where, or under what compliance burden.
each entry carries a relevance note distinguishing tailwinds, headwinds, and no-ops for the platform. source citations link the original .gov record where available; entries lock to citation before publication.
this page is intelligence, not legal advice. creators operating across jurisdictions should retain their own counsel.
